Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Howard M. Saul"'
Autor:
Howard M. Saul, Pamela H. Berger
Publikováno v:
AORN Journal. 52:1212-1228
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b9e22ff748e413c49c9f7f7159f09fe
https://doi.org/10.1016/s0001-2092(07)69199-6
https://doi.org/10.1016/s0001-2092(07)69199-6
Publikováno v:
Gynecologic oncology. 77(3)
Objective. A phase II study of Mifepristone (RU486) was conducted in patients with ovarian cancer whose tumors were resistant to cisplatin and paclitaxel, alone or in combination. Patients and Methods. Forty-four patients were accrued into this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a65d7c85a9bd0080a66cbd35f14ef0
https://pubmed.ncbi.nlm.nih.gov/10831354
https://pubmed.ncbi.nlm.nih.gov/10831354
Autor:
Thomas V. Sedlacek, J.M. Riva, Mark Maslack, Robert Bertoli, Howard M. Saul, John R. Glassburn, Paul Heller, Jeffrey K. Lin
Publikováno v:
Journal of Osteopathic Medicine. 96:727-727
The use of radioactive colloidal phosphorus 32 (3ZP) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ffc7430a1fa76659e85ff2082fb30e1
https://doi.org/10.7556/jaoa.1996.96.12.727
https://doi.org/10.7556/jaoa.1996.96.12.727
Autor:
Michael B. Grossman, Howard M. Saul
Publikováno v:
American Journal of Obstetrics and Gynecology. 158:576-577
Chlamydia trachomatis is becoming increasingly known for its ability to cause severe injury to the female genital tract. Little investigation has been done in its role in diseases of Bartholin's glands. We present what we believe to be the first case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3262fa1b37b18302687dcdd76ee02f1e
https://doi.org/10.1016/0002-9378(88)90029-4
https://doi.org/10.1016/0002-9378(88)90029-4